Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Nasdaq Biotechnology

111.73
+1.961.79%
Post-market: 111.22-0.5147-0.46%19:30 EDT
Volume:5K
Turnover:586.60K
Market Cap:97.21M
PE:- -
High:112.38
Open:110.00
Low:109.95
Close:109.77
52wk High:126.40
52wk Low:55.34
Shares:870.00K
Float Shares:870.00K
Volume Ratio:0.36
T/O Rate:0.61%
Dividend:0.32
Dividend Rate:0.28%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Assembly Biosciences - Gilead Retains Sole Right for Clinical Development and Commercialization of Hsv Hpi Program

THOMSON REUTERS
·
Sep 09

Amgen Stock Poised for Worst Day in More than Two Decades

Dow Jones
·
Sep 09

Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.06% on Sep 8: What Signal Does It Send?

TradingKey
·
Sep 09

Top Midday Decliners

MT Newswires Live
·
Sep 09

Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Sep 8: Drivers Behind the Movement

TradingKey
·
Sep 09

Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says

MT Newswires Live
·
Sep 09

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines

THOMSON REUTERS
·
Sep 09

Royalty Pharma Falls After Novartis' Cholesterol Drug Fails in Study

Reuters
·
Sep 09

Amgen Pulls Dow Industrials Lower; Oil Jumps on Houthi Strikes in Saudi Arabia

Dow Jones
·
Sep 09

Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon

MT Newswires Live
·
Sep 08

NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-09-08

Reuters
·
Sep 08

Amgen Says Phase 3 Study Meets Primary Endpoint in Small Cell Lung Cancer

MT Newswires Live
·
Sep 08

Amgen Inc Stock (AMGN) Moved Down by 8.33% on Sep 8: A Full Analysis

TradingKey
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Dow Drops 438 Points on Losses for Amgen, Salesforce Shares

Dow Jones
·
Sep 08

Amgen Down Nearly 7%, on Pace for Largest Percent Decrease Since March 2020

Dow Jones
·
Sep 08

Amgen-AstraZeneca Cancer Drug Combo Hits Main Survival Goal in Late-Stage Trial

Reuters
·
Sep 08

AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab

TIPRANKS
·
Sep 08

Amgen - Phase 3 Dellphi-305 Study Delivers Significant Overall Survival Benefit Versus Durvalumab Alone

THOMSON REUTERS
·
Sep 08

Imdelltra® in Combination with Imfinzi® Demonstrated Landmark Improvement in Overall Survival in First-Line Extensive Stage Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 08